Indian Drugmakers Seek U.S. Tariff Relief Through Talks
Hyderabad, February 20 – Indian pharmaceutical companies are looking to bilateral discussions with the United States to avoid potential tariffs of at least 25% on drug imports proposed by President Donald Trump, according to a trade association.
India, often referred to as the "pharmacy of the world," is known for producing affordable generic drugs. These medicines are manufactured in large factories across the country and are exported to more than 200 nations, with the U.S. being the largest market. Government data indicates that in fiscal year 2024, exports to the U.S. amounted to $8.7 billion, which is about 31% of India’s total pharmaceutical exports. The announcement of the tariff plan has caused a drop in stock prices for Indian drugmakers.
Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance, shared on Wednesday that ongoing discussions between the two nations will shape the next steps regarding the tariffs. He expressed optimism that continuous communication among all parties will lead to a positive outcome.
Research from IQVIA highlights the significance of Indian drug manufacturers, noting that in 2022, they accounted for nearly half of all prescriptions for generic medicines in the U.S. This industry plays a critical role in providing affordable and high-quality medications, saving the U.S. healthcare system around $408 billion that year.
Analyst Vishal Manchanda from Systematix Institutional Equities pointed out that implementing these tariffs could lead to increased inflation in the U.S., as there is not enough domestic manufacturing capacity to replace the volumes supplied by India.
The Indian Pharmaceutical Alliance includes major companies like Sun Pharmaceutical, Dr. Reddy’s, Cipla, and Zydus Lifesciences, as well as U.S. firms like Abbott operating in India. Recently, Sun Pharma Managing Director Dilip Shanghvi mentioned that if the tariffs go into effect, the extra costs will eventually be passed down to consumers.
As discussions progress, the future of these tariffs and their impact on the pharmaceutical landscape remains to be seen.
